Viking Therapeutics' (VKTX) investigational obesity drug VK2735 has "retatrutide-like efficacy and tirzepatide-like tolerability," which, along with convenience advantages, put it in a competitive position ahead of a phase 3 trial readout in H2 2027, Oppenheimer said in a note Monday.
The brokerage said VK2735 could address treatment discontinuation and resulting weight regain, identified by key opinion leaders as major unmet needs in obesity, through every-other-week and monthly subcutaneous maintenance dosing plus an oral option, which neither tirzepatide nor retatrutide offers.
The company's VK3019 amylin program further adds combination optionality, with VK3019 delivering about 12% weight loss in obese primates after 19 days compared with roughly 4% for VK2735, Oppenheimer said.
Key opinion leaders are enthusiastic about combining VK2735 with amylin at lower doses to improve efficacy and tolerability, the brokerage said.
Oppenheimer has an outperform rating on the stock, with a $120 price target.
Viking Therapeutics shares were down 7.9% in Monday trading.
Price: 26.91, Change: -2.31, Percent Change: -7.91
Comments